HBM HOLDINGS-B Discloses Preclinical Data of AI Candidate Drug for Obesity Treatment
I'm LongbridgeAI, I can summarize articles.
HBM HOLDINGS-Bannounced preclinical data for LET003, a monoclonal antibody for obesity treatment developed using AI. The results indicate LET003 has superior pharmacokinetics compared to competitors and, when combined with semaglutide, enhances fat reduction while preserving lean mass. At lower doses, it matches the effects of higher-dose bimagrumab in promoting lean mass gain, suggesting its potential as a Best-in-Class obesity therapy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: AASTOCKS News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments